@article {FinamoreS31.005作者= {Jon Finamore迈克尔·斯珀林和婷婷詹和克里斯托弗•斯基德莫尔Maromi Nei和斯科特·明茨},title ={开关抗癫痫药物后发作的结果:一个匹配,前瞻性研究(S31.005)},体积={84}={14}补充数量,elocation-id = {S31.005} ={2015},出版商= {Wolters Kluwer健康,公司代表美国神经病学学会},文摘={摘要目的:探讨结果改变后的抗癫痫药物(aed)局灶性癫痫患者在控制,未来的时尚。首页背景:改变AED治疗后结果很大程度上是在案例学习系列。我们组最近报道首次研究检查控制方式。在这里,我们报告的结果改变AED疗法,在耐火材料的病人和那些在缓解,AED,使用一种改进的控制,前瞻性研究设计。设计/方法:我们发现局灶性癫痫患者采取单一AED看到在我们中心的九个月的时间。切换到另一台AED的单一疗法被认为是病人,而那些仍在同一药物作为控制。我们匹配情况下控制基于癫痫状态(癫痫发作前6个月),当前AED,和之前AED的数量。我们前瞻性地遵循这些病人和重新发作状态在6个月后,索引日期。结果:患者在控制发作了药物(n = 13), 15.4 (percnt)反复发作,相比7.7 [percnt]复发之间的控制保持在同一药物(n = 39;p = 0.59)。 Among non-seizure-free patients who switched drugs (n=29), 41.4[percnt] had a 6-month remission, compared to 55.2[percnt] controls remaining on the same drug (n=29; p=0.43). Those who had tried 2 or more other AEDs in the past were less likely to enter remission than those who had tried 1 or none (p=0.015). CONCLUSIONS:For seizure-free patients, we found a modest, non-significant risk (~8[percnt]) of seizure recurrence associated with changing medication. Non-seizure-free patients were at least as likely to enter remission on the same drug as with a different drug, suggesting that most positive outcomes in this group are due to spontaneous remission, not drug response.Disclosure: Dr. Finamore has nothing to disclose. Dr. Sperling has received personal compensation for activities with UCB Pharma as a consultant. Dr. Sperling has received personal compensation in an editorial capacity for Epilepsia. Dr. Sperling{\textquoteright}s employer has received research support from Sunovion, Ei Dr. Zhan has nothing to disclose. Dr. Skidmore has received personal compensation for activities with Upsher-Smith Laboratories, Inc. as a consultant. Dr. Nei has received research support from Medtronic Inc., Neuropace, GlaxoSmithKline, UCB Pharma, Marinus, and Ortho-McNeil/Johnson \& Johnson. Dr. Mintzer has received personal compensation for activities with UCB Pharma, Sunovion, Upsher-Smith Laboratories, Pfizer Inc., SK Pharmaceuticals, Vertex Pharmaceuticals, and Eisai Inc. as a speaker and/or consultant.Wednesday, April 22 2015, 4:00 pm-5:45 pm}, issn = {0028-3878}, URL = {//www.ez-admanager.com/content/84/14_Supplement/S31.005}, eprint = {//www.ez-admanager.com/content}, journal = {Neurology} }